Date: 2015-02-17
Type of information: Licensing agreement
Compound: EP-3102 (bendamustine hydrochloride)
Company: Teva Pharmaceutical Industries (Israel) Eagle Pharmaceuticals (USA - NJ)
Therapeutic area: Cancer - Oncology
Type agreement: licensing
Action mechanism:
Disease: chronic lymphocytic leukemia, indolent B-cell non-Hodgkin lymphoma
Details: * On February 17, 2015, Teva Pharmaceutical Industries and Eagle Pharmaceuticals announce that the companies have entered into an exclusive license agreement for EP-3102, Eagle\'s bendamustine hydrochloride (HCl) rapid infusion product for the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma ( NHL ). Teva will be responsible for all U.S. commercial activities for the product including promotion and distribution. Eagle has responsibility for obtaining all regulatory approvals, conducting post-approval clinical studies, if required, and initially supplying drug product to Teva. Eagle has submitted a New Drug Application (NDA) to the FDA for the rapid infusion bendamustine product for the treatment of patients with CLL and patients with indolent B-cell NHL that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Eagle has requested Priority Review of the NDA; this product candidate has received Orphan Drug Designations for both CLL and indolent B-cell NHL , and therefore may be eligible for seven years of exclusivity upon approval. The NDA is supported by data from Eagle\'s recently-completed clinical trials demonstrating that the rapid infusion bendamustine HCl product can be administered in ten minutes in a low-volume, 50 mL admixture. As part of the agreement, Teva will waive its orphan drug exclusivities for NHL and CLL with respect to EP-3102, which should allow the product to come to market more quickly. The companies will also settle the pending patent infringement action between them in the United States District Court for the District of Delaware involving Teva\'s U.S. Patent No. 8,791,270.
Financial terms: Under the terms of the exclusive license agreement, Eagle will receive an upfront cash payment of $30 million and is eligible to receive up to $90 million in additional milestone payments. In addition, Eagle will receive double-digit royalties on net sales of the product, assuming FDA approval.
Latest news:
